The Only Patient in the Building Who Gains Nothing From the Operation
A healthy woman about to give up a kidney for her brother forces the team to weigh an opioid-sparing painkiller against a guideline caution built on no real evidence at all — in the one surgical patient whose remaining organ has to work perfectly for the rest of her life.
Denise F., a 52-year-old accountant, is scheduled for laparoscopic living-donor nephrectomy next week to give her younger brother the kidney his diabetes has been slowly taking from him for a decade, a decision she describes as one she made the day his nephrologist first mentioned dialysis and never seriously reconsidered afterward. She is in excellent health in her own right — normal blood pressure without medication, no diabetes of her own despite family history on both sides, a body mass index of 24, and a pre-donation eGFR of 98 — and has passed every stage of donor evaluation, medical and psychosocial, without a single flagged concern. She will walk out of the operating room with one kidney doing the work two used to do, for the rest of a life she otherwise has no medical reason to have altered at all — a fact her independent living donor advocate raised explicitly and by name at her final pre-operative visit, not as a discouragement from proceeding, but as the frame the whole team is supposed to keep in view for every decision still ahead of them.
Her surgical team's enhanced-recovery pathway includes ketorolac as part of a multimodal, opioid-sparing analgesia plan, matching Campsen and colleagues' 2019 double-blind randomized trial that compared exactly this ERAS approach against standard opioid-based care in living kidney donors specifically, and found real reductions in narcotic consumption with no signal of impaired recovery in that trial population. Set against that trial is the standing guideline caution against NSAID use in living kidney donors — a caution Laube and colleagues' 2025 retrospective review of real-world prescribing patterns found was built on expert opinion rather than actual outcome data, since almost no study has directly measured post-donation renal function in donors who did or didn't receive one. On the other side of the same ledger sits venous thromboembolism prophylaxis: a prospective Swedish cohort study using structured pre- and post-operative screening alongside mechanical prophylaxis alone, without routine pharmacologic anticoagulation in average-risk donors, measured a genuinely low VTE rate across its full cohort — a real comparison point for how much prophylactic intensity her own unremarkable risk profile actually calls for, rather than a default answer applied the same way to every surgical patient regardless of risk.
Pre-operative planning for someone with nothing to gain
Ketorolac stays in the pathway. Campsen and colleagues' 2019 trial was a double-blind randomized comparison of this exact ERAS approach — ketorolac and pregabalin — against standard opioid-based care specifically in living donor nephrectomy, and found real reductions in opioid consumption with no signal of impaired recovery.
I take the caution about her remaining kidney seriously — it's exactly why I'd rather use a trial run in living donors specifically than extrapolate a caution written for a general surgical population where the guideline's own recent review found it was never actually evidence-based to begin with.
I don't dispute the trial data on opioid reduction. What I'd hold onto is that she is the one patient in this entire process who gains nothing medically from what's about to happen to her — every other surgical decision in transplant medicine is made for someone who benefits from accepting some risk. She isn't.
Saying the caution 'was never evidence-based to begin with' cuts both ways — it means we don't actually know the renal risk is zero, not that we've confirmed it is. In someone about to have no reserve kidney for the rest of her life, I'd rather accept a little more opioid than gamble on an unmeasured risk to the one organ she has left, however small that risk is thought to be.
On the analgesia question, I'd side with a compromise: a single, limited course of ketorolac at reduced dose and duration rather than the full protocol, given her BMI, her negative history, and the fact that the trial evidence, while real, is still a single study rather than a settled standard.
On thromboprophylaxis, though, I want to be precise about what 'maximum caution' actually costs her. A prospective Swedish cohort using structured screening and mechanical prophylaxis alone in average-risk donors found a genuinely low VTE rate — she has none of that cohort's risk factors. Adding routine pharmacologic anticoagulation on top of that baseline doesn't protect her remaining kidney; it just adds a real bleeding-risk cost to a person with no risk factor the prophylaxis is actually meant to address.
Agreed: a reduced-dose, limited-duration ketorolac course within an otherwise standard multimodal pathway, and mechanical thromboprophylaxis alone without routine pharmacologic anticoagulation, given her absence of any measured risk factor for either renal harm or venous thromboembolism. The surgeon's proposed middle dose was what actually resolved the analgesia disagreement — not a retreat from the trial evidence, but a scaled version of it that answered the advocate's concern without abandoning the protocol.
The advocate's underlying position — that a donor who gains nothing shouldn't absorb even an unconfirmed risk on the same terms a therapeutic patient would — was never fully argued away, only accommodated by a smaller dose than the trial protocol itself used. Nobody at the table treated that as a compromise of the evidence; they treated it as a reasonable adjustment for the one person in the room with nothing to gain from being wrong.